About Clinical Research Centre
Sunway Medical Centre’s Clinical Research Centre (SunMed CRC) commenced in August 2009 in response to the demand for evidence-based practice as well as SunMed’s wish to participate significantly in medical research. CRC is dedicated primarily towards coordinating all research involving human subjects. Such research studies may be related to:
- pharmaceutical products,
- medical devices,
- medical radiation and imaging,
- surgical procedures,
- medical records,
- biological samples,
- and/or epidemiological, social and psychological investigations.
CRC seeks to promote ethical and reliable clinical research according to the international and local Good Clinical Practice (GCP) standards. We bridge communication between investigators and their counterparts; and assist with feasibility assessments conducted by interested parties. Apart from facilitating SunMed to secure research projects, we assist in documenting and tracking progress of the clinical researches conducted. In response to the demand for evidence-based clinical research, we seek to increase participation of SunMed and to contribute significantly to the health and research industry.
VISION
To be the leading and pioneering centre of excellence in ASEAN region for research in a private hospital.
MISSION
To create a sustainable research ecosystem in Sunway Medical Centre by enabling medical staff and professionals to learn and discover with the goal to provide the best patient care.
GOAL
To set up a Clinical Research Centre (CRC) for the conduct of quality clinical trials and research according to Good Clinical Practice (GCP) for the advancement of medicine and to improve Quality of Life for the patients.
OBJECTIVES
- Set up a strong governance structure within Clinical Research Centre (CRC) to facilitate communication, approval process and quality research conducts which benefits and improves the quality of life for the patients.
- To set up comprehensive infrastructure and facilities to support research.
- Foster strong research culture among consultants, allied healthcare partners and nursing staffs, and establish research identity.
- Establish SunMed as partner of choice for research collaboration among CROs, Industry, Academia & Community.
SERVICES
Clinical Research Centre (CRC), established within Sunway Medical Centre, is essential to the conduct of clinical research initiated in SunMed and therefore the facilities and resources are made available to meet the needs of sponsors/contract research organization (CRO), investigators, and all subjects. Such services include:
- Feasibility Studies
CRC assists consultants to review feasibility of protocols received from pharmaceutical companies or CROs, taking into consideration of the resources, patient pool, patient indication, facilities and services required in conducting the study in an institution. - Ethics Review
We have an institutional committee, the Sunway Medical Centre Independent Research Ethics Committee (SREC) constituted of medical professionals and non-medical members, whose responsibility is to ensure the rights, safety and well-being of human subjects involved in a clinical trial. It is compulsory for all studies involving human subjects at SunMed to be reviewed and approved by SREC for conduct. - Legal Review
We have in-house legal advisor that review the provisions of the agreements involved. - Pre-Clinical Trial Organising and Planning
CRC reviews the trial design and procedures to ensure that SunMed has the expertise and facilities to conduct the relevant procedures. CRC liaises and discusses with relevant departments and consultants on the protocol procedures to ensure any concerns are dealt with efficiently. - Clinical Trial Operations
Managing key deliverable issues, personnel, data, finance and operational matters in line with hospital policies to meet sponsor/CRO’s, GCP and regulatory requirements. - Site initiation and closure
We provide venue for site initiation and closure. CRC ensures that all pre-initiation and initiation procedures are performed accordingly to meet GCP and regulatory requirements.
ORGANIZATION CHART
INDUSTRY SPONSORED RESEARCH (ISR)
Active Clinical Trials
The list of clinical trials that are currently active at Sunway Medical Centre. For those who are interested to participate in the current clinical trials, please contact us.
No. | Study Title | Targeted Patients | Recruitment Status |
1. |
A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/μL) |
Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia |
Recruiting |
2. |
MANIFEST-2: A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI‑0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients |
Patients with Myelofibrosis |
Recruiting |
3. |
KontRASt-02: A Randomized, Controlled, Open-label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 versus Docetaxel in Previously Treated Subjects with Locally Advanced or Metastatic KRAS G12C Mutant Non-Small Cell Lung Cancer |
Patients with non-small cell lung cancer |
Recruiting |
4. |
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in addition to R-CHOP versus R-CHOP in Previously Untreated, High-Intermediate and High-risk Patients with Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) |
Patients with newly-diagnosed diffuse large B-cell lymphoma |
Recruiting |
5. |
A Phase III, Open-Label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy (PALOMA-3) |
Patients with Metastatic Non-Small Cell Lung Cancer (Stage 4) |
Recruiting |
6. |
A Phase III, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer |
Patients with bladder cancer |
Recruiting |
7. |
The ARiCa Study: Use of an online Asian Genetic Risk Calculator to improve the uptake of genetic counselling and genetic testing among breast cancer patients |
Breast Cancer |
Recruiting |
8. |
Phase II/III Multicenter, Randomized, Double-blind, Placebo-controlled Study in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA) to Evaluate the Efficacy and Safety of an Intravenous Biologic Therapy, followed by an Open-label Extension Period |
Autoimmune Hemolytic Anemia (wAIHA) |
Initiating |
9. |
A Phase 3 Study Utilizing a Minimal Residual Disease Directed Approach to Evaluate the Combination of Amivantamaband Lazertinib versus Single Agent Osimertinib in the Adjuvant Treatment of Patients with Resected EGFR-Mutated Non-Small Cell Lung Cancer (Adonis) |
Resected EGFR-Mutated Non-Small Cell Lung Cancer (Adonis) |
Initiating |
10. |
CABL001J12302: Feasibility Survey for Asciminib in 1L CML A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase |
Myelogenous Leukemia |
Initiating |
11. |
Observational study to evaluate the actual use of Elidel in South and East Asian Patients from 3 months to 12 years with mild moderate atopic dermatitis |
Mild moderate atopic dermatitis |
Study awarded |
12. |
A Phase 3b, multicenter, randomized, double-blind, placebo-controlled, 3-arm study of guselkumab 100 mg administered subcutaneously (SC) at Weeks 0, 4, and q8w thereafter or 100 mg SC q4w through Week 48 in participants with active PSA who are biologic naïve and have had inadequate response to current standard therapies. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) |
Psoriatic arthritis |
Initiating |
13. |
Randomized, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa |
Hidradenitis suppurativa |
Initiating |
14. |
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) |
Viral Lung Infection |
Study awarded |
15. |
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome |
Patients with Netherton syndrome |
Initiating |
INVESTIGATOR INITIATED RESEARCH (IIR)
RESEARCH OUTPUT
Top 5 most cited research output. For the full list of research outputs, please click the link here.
CRC Policies and Procedures
Policy number |
Policy name |
Applicability |
---|---|---|
SMC-SOS-CORP-CRC-001 |
Scope of Services |
IIR |
SMC-GL-CORP-CRC-001 |
Prepare for an Audit or Inspection |
IIR |
SMC-GL-CORP-CRC-002 |
External Grant Application for Investigator Initiated Research (IIR) |
IIR |
SMC-GL-CORP-CRC-003 |
Grand Management for Investigator Initiated Research (IIR) |
IIR |
SMC-SOP-CORP-CRC-007 |
Request for Research collaboration with SunMed |
IIR |
SMC-SOP-CORP-CRC-008 |
SunMed Funding Application |
IIR, IISR |
SMC-SOP-CORP-CRC-009 |
Document Control for research Related Documents |
ISR, IISR |
SMC-SOP-CORP-CRC-010 |
Protocol Development |
IISR (if applicable), IIR |
SMC-SOP-CORP-CRC-013 |
Informed Consent Process |
IIR, IISR, ISR |
SMC-SOP-CORP-CRC-016 |
Re-consent process |
IIR, IISR, ISR |
SMC-SOP-CORP-CRC-017 |
Taking Informed Assent Process |
IIR, IISR, ISR |
SMC-SOP-CORP-CRC-019 |
Research Team Training |
IIR, IISR, ISR |
SMC-SOP-CORP-CRC-020 |
Handling of Research Noncompliance |
IIR, ISR, IISR |
SMC-SOP-CORP-CRC-021 |
Assisting in Site Initiation Visit for ISR |
ISR |
SMC-SOP-CORP-CRC-022 |
Assisting in (COV) for Industry Sponsored Research (ISR) |
ISR |
SMC-SOP-CORP-CRC-023 |
Assisting in Archiving in (ISR) |
ISR |
SMC-SOP-CORP-CRC-027 |
Safety Surveillance Management |
ISR, IISR |
SMC-SOP-CORP-CRC-028 |
Research Sample Management |
ISR |
SMC-SOP-CORP-CRC-029 |
Submitting Study Progress Report & End of Research Report |
IIR |
SMC-SOP-CORP-CRC-030 |
Laboratory Specimen Handling & Shipment in ISR |
ISR |
SMC-SOP-CORP-CRC-031 |
Investigational Product (IP) Management |
ISR, IISR |
SMC-SOP-CORP-CRC-032 |
Investigational Product (IP) Dispensing |
ISR, IISR |
SMC-SOP-CORP-CRC-033 |
Study Closeout for Investigator Initiated Research (IIR) |
IISR (If applicable) |
SMC-SOP-CORP-CRC-034 |
Site Initiation for Investigator Initiated Research (IIR) |
IIR |
SMC-SOP-CORP-CRC-035 |
Maintaining Study Documentation & Record Keeping in Industry Sponsored Research |
ISR, IISR |
SMC-SOP-CORP-CRC-036 |
Monitoring of Investigator Initiated Research (IIR) |
IIR |
SMC-SOP-CORP-CRC-037 |
Handling Feasibility Studies |
ISR |
SMC-SOP-CORP-CRC-038 |
Research Misconduct |
ISR, IISR, IIR |
SMC-SOP-CORP-CRC-039 |
Pre -Publication Submission Review |
IISR |
- Request for policies or Standard Operating Procedures, please write to: Head of Department, Clinical Research Centre at [email protected] .
- SunMed employee may access CRC policies and procedures via shared point.
- Applicant shall read through the relevant policies and procedures prior to the commencement of your research project.
About SunMed Independent Research Ethics Committee (SREC)
The Sunway Medical Centre Independent Research Ethics Committee (SREC) is a committee established under the authority of Sunway Medical Centre Berhad (SunMed). It evaluates the ethical aspects of research in SunMed, ensuring that they are reliably conducted in accordance with both international and Malaysian standards of ‘Good Clinical Practice’ (GCP).
SREC holds as its primary responsibility the safe-guarding of the rights, safety, and well-being of all research subjects. As per GCP requirements, members of the SREC are drawn from medical and non-medical sectors to ensure sufficient objectivity and independence from SunMed clinicians undertaking the research. The Clinical Research Centre (CRC) is the Secretariat to SREC
Registered with National Pharmaceutical Regulatory Agency (NPRA)
Sunway Medical Centre Independent Research Ethics Committee (SREC) is one of the 3 private hospital among the 13 Ethics Committee Registered with Drug Control Activity (DCA)
Objective
The objectives of SREC are to
- protect the rights, safety, dignity and wellbeing of the subjects of research
- promote ethical principles in human research
- provide special attention to research involving vulnerable subjects and use of genetic testing
- facilitate ethical research through efficient and effective review processes
- provide competent review and monitoring of human research projects whilst they are active
- promote awareness of the ethical conduct of human research
Scope
The scope of the SREC’s operations manual is applicable to all members of SREC and persons conducting research in SunMed. The scope also encompasses the following:
Terms of reference of the SREC which include:
- responsibilities,
- membership requirements,
- terms of appointment,
- liability coverage,
- conditions of appointment,
- offices, quorum & meeting requirements,
- use of independent panel and
- education of members.
- procedure for submitting an application to the SREC for
- approval to conduct research projects or to make amendments to a previously SREC approved research,
- Reviewing of applications by SREC,
- decision-making and the communication of decisions of the SREC,
- following up and monitoring of approved research,
- SREC documentation and archiving.
SREC Member (Term 2022-2023)
Name |
Gender |
Earned Degree |
Primary Specialty |
Occupation |
Affiliation With SunMed |
---|---|---|---|---|---|
Dato’ Dr. Chang Kian Meng (Chairperson) |
M |
MBBS,MRCP,FRCP,FRCPA (Haem) |
Scientific |
Consultant Haematologist |
Yes |
Assoc. Prof. Dr. Quek Kia Fatt (Vice-Chairperson) |
M |
PhD, FRIPH |
Scientific |
Lecturer of Community Health, Jeffrey Cheah School of Medicine & Health Sciences |
No |
Mr. Edwin Tan (Secretary) |
M |
BSc |
Scientific |
Senior Manager, CRC |
Yes |
Ms. Azliana Binti Abu Bakar Sajak |
F |
BSc, MSC |
Scientific |
Research Scientist |
Yes |
Prof. Dr. Abhi Veerakumarasivam |
M |
PhD (Oncology & Genetics) |
Scientific |
Professor, Department of Medical Sciences |
No |
Mr. Lau Ngee Boon |
M |
NA |
Non-scientific |
Business Manager |
No |
Mr. Mah Seng Cheng |
M |
MCE |
Non-scientific |
Sales Manager |
No |
Dr. Felix Yap Boon Bin |
M |
MD (UNIMAS) MRCP (UK) AdvMDerm (UKM) |
Scientific |
Consultant Dermatologist |
Yes |
Ms. Wan Mun Yi |
F |
Pharmacy |
Scientific |
Assistant Manager, Pharmacy |
Yes |
Mr. Ashwin A/L Kumar |
M |
LL.B |
Non-scientific |
Senior Manager, Legal Services |
Yes |
Ms. Amy Khoo Leet Chien |
F |
LL.B |
Non-scientific |
Director, Legal Services |
Yes |
Dr. Jennifer Leong Siew Mooi |
F |
MBBS (IMU), MCO (UM) |
Scientific |
Consultant Clinical Oncologist |
Yes |
Dr. Thangesweran Ayakannu |
M |
MBBS (Trinidad, West Indies), MLiP (UK), DFFP (UK), MRCOG (UK), PhD (UK), Colposcopist (UK), Laparoscopic Pelvic Surgeon (UK), INTUITIVE Registered Gynaecological Robotic Surgeon (UK), British & Irish Association Registered Robotic Gynaecological Surgeon (UK) |
Scientific |
Consultant Obstetrics & Gynecology-Oncologist |
Yes |
SREC Meeting Dates and Application Submission Due Date
Please click here to download for 2023 SREC meeting dates and application due date. Applicant may also contact the SREC secretariat to confirm the SREC meeting dates and application due date.
Overview of Conducting Research in Sunway Medical Centre

All research projects to be conducted in SunMed MUST obtain research ethic committee and institutional approvals.
Ethics Application
Please refer to SREC Application Guidelines on how to apply:
SREC Form | Checklist |
---|---|
Research Amendment Application Form |
Informed Consent Form & Written Subject Information Checklist |
Genetic Research Checklist | |
Institutional Approval
- SunMed Research Request Form (SMRR) completion
Principal investigator is required to complete the SunMed Research Request Form (SMRR) and read the Sunway Anti Bribery and Corruption (ABC) policies together with related CRC policies and procedures. Attach proposal and all written information that you are providing to research subject.
- Departmental Approval
Investigator has to approach the related department(s)’ Head for the approval(s). For instance, if your research involving nurses, then you are required to approach the Director of Nursing. If SunMed staff is the target subjects, then you should obtain the approval from Medical Director/Chief Executive Officer (CEO). If you are unsure which department to approach you may contact us.
Departmental Approval for SunMed
Sunway Medical Centre (SunMed) should be done via the link:- https://bit.ly/3ktQAwa
Submitting the SMRR form, Departmental Approval and a copy of your research proposal
Please submit the following to [email protected] :-
a) Signed and dated SMRR form
b) Signed and dated ABC declaration form (appendix of SMRR)
c) A copy of your recent research proposal with version and date
Kindly ensure all the documents are submitted to avoid delay of your research approval. Please take note that the department approval(s) is/are compulsory for feasibility assessment.
- Institutional Approval
This will commence after the completion of feasibility assessment and scientific review. If the project is approved by Sunway CRC Research Board (SRB) the investigator will receive an institutional approval letter.
For Sunway Medical Velocity (SMCV), you are required to complete the Institutional Approval Form.
- Research Agreement
Preparation and signing of collaborative research agreement
CRC will contact you if an agreement is required. We may provide the agreement template to the collaborator for review and comment. Once all parties agreed and signed the agreement then only the study could be initiated.
Research Reporting
i. Research Progress Report - Download Here
- Research under investigator initiated research initiated Research (IIR) is required to submit research report annually every 6 months
ii. End of Research (EOR) Report - Download Here
- Research under investigator initiated research initiated Research (IIR) is required to submit research report annually every 6 months
iii. Pre-publication Submission Review - Download Here
Send a copy of your drafted publication materials to [email protected] prior submission for publication. After publication a copy of the publication shall be submitted to delegated CRC staff. Furthermore, acknowledgement to Sunway Medical Centre is required for funded research. This applicable for any research project that conducted in Sunway Medical Centre.
Note: This ONLY applicable for research project conducted Sunway Medical Centre
Research Non-Compliance & Protocol Deviation Reporting
For Investigator Initiated Research (IIR) which does not involve investigational products (Clinical Trial), submit Research Noncompliance Form to CRC.
For Industry Sponsor Research (ISR) which involves investigational products (Clinical Trial), submit SREC Protocol Deviation Reporting Form.
Reporting Timeline - Minor within 30 days, Major within 7 days (calendar date).
Internship and Attachment
If you are interested to apply for attachment or internship at SunMed CRC, kindly send your application to [email protected] with the following documents:
- A cover letter addressing to Head of Division, Clinical Research and Medical Education, Sunway Medical Centre
- A copy of your resume
Operation hours
8.00 am - 5.30 pm
Inquiry
For any inquiry and feedback, please contact Clinical Research Center (CRC) at [email protected].
Contact Us
Address | SunMed Clinical Research Centre, F-03-02, Block F, Sunway Geo Avenue, Jalan Lagoon Selatan, Bandar Sunway, 47500 Selangor |
Tel No | +603 8601 1072 +603 8601 1079 +603 8601 1080 |
Fax No | +603 8601 1069 |
[email protected] [email protected] |
Accreditation
Australian Council on Healthcare Standards (ACHSI)
Malaysian Society for Quality in Health
Useful Links
National Medical Research Registry (NMRR)
Clinical Research Centre – Ministry of Health Malaysia (CRC-MOH)
Medical Device Authority (MDA)- Ministry of Health Malaysia
Guidelines for Stem Cell Research and Therapy – Ministry of Health Malaysia
Society of Clinical Research Professionals Malaysia (SCRPM)
National Committee for Clinical Research (NCCR)
National Pharmaceutical Regulatory Agency (NPRA)
ClinicalTrials.gov – Registry of Clinical Trials in U.S. and around the world